Comprehensive Pneumology Center (CPC), University Hospital, Ludwig-Maximilians University, Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany
Auto-generated profile, based on publicly available information
Ilona Elisabeth Kammerl
Comprehensive Pneumology Center (CPC), University Hospital, Ludwig-Maximilians University, Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany
The proteasome system degrades more than 80% of intracellular proteins into small peptides. Accordingly, the proteasome is involved in many essential cellular functions, such as protein quality control, transcription, immune responses, cell signaling, and apoptosis. Moreover, degradation products are loaded onto major histocompatibility class I molecules to communicate the intracellular protein composition to the immune system. The standard 20S proteasome core complex contains three distinct catalytic active sites that are exchanged upon stimulation with inflammatory cytokines to form the so-called immunoproteasome. Immunoproteasomes are constitutively expressed in immune cells and have different proteolytic activities compared with standard proteasomes. They are rapidly induced in parenchymal cells upon intracellular pathogen infection and are crucial for priming effective CD8+T-cell-mediated immune responses against infected cells. Beyond shaping these adaptive immune reactions, immunoproteasomes also regulate the function of immune cells by degradation of inflammatory and immune mediators. Accordingly, they emerge as novel regulators of innate immune responses. The recently unraveled impairment of immunoproteasome function by environmental challenges and by genetic variations of immunoproteasome genes might represent a currently underestimated risk factor for the development and progression of lung diseases. In particular, immunoproteasome dysfunction will dampen resolution of infections, thereby promoting exacerbations, may foster autoimmunity in chronic lung diseases, and possibly contributes to immune evasion of tumor cells. Novel pharmacological tools, such as site-specific inhibitors of the immunoproteasome, as well as activity-based probes, however, hold promises as innovative therapeutic drugs for respiratory diseases and biomarker profiling, respectively.
Rationale: Patients with chronic obstructive pulmonary disease (COPD) and in particular smokers are more susceptible to respiratory infections contributing to acute exacerbations of disease. The immunoproteasome is a specialized type of proteasome destined to improve major histocompatibility complex (MHC) class I–mediated antigen presentation for the resolution of intracellular infections. Objectives: To characterize immunoproteasome function in COPD and its regulation by cigarette smoke. Methods: Immunoproteasome expression and activity were determined in bronchoalveolar lavage (BAL) and lungs of human donors and patients with COPD or idiopathic pulmonary fibrosis (IPF), as well as in cigarette smoke–exposed mice. Smoke-mediated alterations of immunoproteasome activity and MHC I surface expression were analyzed in human blood-derived macrophages. Immunoproteasome-specific MHC I antigen presentation was evaluated in spleen and lung immune cells that had been smoke-exposed in vitro or in vivo. Measurements and Main Results: Immunoproteasome and MHC I mRNA expression was reduced in BAL cells of patients with COPD and in isolated alveolar macrophages of patients with COPD or IPF. Exposure of immune cells to cigarette smoke extract in vitro reduced immunoproteasome activity and impaired immunoproteasome-specific MHC I antigen presentation. In vivo, acute cigarette smoke exposure dynamically regulated immunoproteasome function and MHC I antigen presentation in mouse BAL cells. End-stage COPD lungs showed markedly impaired immunoproteasome activities. Conclusions: We here show that the activity of the immunoproteasome is impaired by cigarette smoke resulting in reduced MHC I antigen presentation. Regulation of immunoproteasome function by cigarette smoke may thus alter adaptive immune responses and add to prolonged infections and exacerbations in COPD and IPF.
This protocol describes an easy and reliable in-gel proteasome assay to quantify the activity and composition of different proteasome complexes in cells and tissues. The assay works well with limited amounts of total cell protein lysates. Although this assay is optimized specifically for the proteasome chymotrypsin-like activity, it can be expanded to other proteasome activities as well. Using antibodies that detect distinct proteasome subunits or regulators, we can determine the composition and relative quantity of active proteasome complexes.
Mitochondrial dysfunction is a hallmark of IPF and promotes the development of pulmonary fibrosis. Mitochondrial stress can activate innate immunity via mitochondrial (mt) DNA sensing. However, whether mitochondrial stress also regulates adaptive immune is unknown. We here investigated regulation of MHC I antigen presentation by mitochondrial stress using a mouse cell model of chronic mitochondrial dysfunction as well as an acute mtDNA stress model in human primary lung fibroblasts(phLF). Mouse embryonic fibroblasts derived from the mitochondrial function, PolgA mutator mouse model, demonstrated concerted upregulation of the MHC I as revealed by proteomic and FACS analysis. Importantly, expression and activity of the immunoproteasome, a specialized type of proteasome involved in the generation of antigenic MHC I peptides, was strongly upregulated compared to controls. Induction was driven by the activation of STAT1/type I interferon signaling via the cGAS/STING. And CD8+ T cells were activated when co-cultured with the PolgA mutator cells. In phLF, transfected mtDNA increased the immunoproteasome/MHC I and promoted generation of influenza MHC class I antigenic peptides to activate influenza-specific CD8+T cells as shown by FACS analysis and CD8+ T cell activation assays. Furthermore, single cell RNA seq analysis from publicly available ILD data sets revealed an enrichment for type I interferon and MHC I in AT1 and ciliated cells as well as CD8+ T cell responses. In conclusion, dysfunctional mitochondria activate adaptive CD8+ T cell responses via immunoproteasome and MHC I antigen presentation. In the lung, the defective mitochondrial function might contribute to fibrosis via imbalanced MHC class I antigen presentation in lung epithelial cells driving T cell autoimmunity.